Compare XGN & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XGN | GANX |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.2M | 78.2M |
| IPO Year | 2014 | 2021 |
| Metric | XGN | GANX |
|---|---|---|
| Price | $4.51 | $1.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $8.86 | $7.50 |
| AVG Volume (30 Days) | 384.6K | ★ 694.3K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $55,180.00 |
| Revenue This Year | $8.12 | N/A |
| Revenue Next Year | $13.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.59 | $1.41 |
| 52 Week High | $12.23 | $4.34 |
| Indicator | XGN | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 55.83 | 50.89 |
| Support Level | $2.68 | $1.65 |
| Resistance Level | $5.55 | $2.12 |
| Average True Range (ATR) | 0.39 | 0.12 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 30.21 | 48.98 |
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.